Experienced in Chronic Familial Neutropenia

Dr. Lea N. Baer

Hematology Oncology | Oncology
Stony Brook Internists University Faculty Practice Corporation
3 Edmond D Pellegrino Rd, 
Stony Brook, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Chronic Familial Neutropenia
Stony Brook Internists University Faculty Practice Corporation
3 Edmond D Pellegrino Rd, 
Stony Brook, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lea Baer is a Hematologist Oncology specialist and an Oncologist in Stony Brook, New York. Dr. Baer is rated as an Experienced provider by MediFind in the treatment of Chronic Familial Neutropenia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Her clinical research consists of co-authoring 13 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Suny/stony Brook University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

STONY BROOK INTERNISTS UNIVERSITY FACULTY PRACTICE CORPORATION
3 Edmond D Pellegrino Rd, Stony Brook, NY 11794
Other Locations
STONY BROOK INTERNISTS UNIVERSITY FACULTY PRACTICE CORPORATION
26 Research Way, East Setauket, NY 11733

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Unknown
Publish Date: October 15, 2021
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer
A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer
Enrollment Status: Withdrawn
Publish Date: July 16, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 8 Less Clinical Trials

13 Total Publications

Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study.
Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study.
Journal: Breast cancer research and treatment
Published: February 13, 2025
Similar Doctors
Distinguished in Chronic Familial Neutropenia
Dr. Michael J. Maresca
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Familial Neutropenia
Dr. Michael J. Maresca
Hematology Oncology | Hematology | Oncology

North Shore Hematology Oncology Associates PC

48 Route 25a, 
Smithtown, NY 
 (5.0 miles away)
631-751-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Maresca is a Hematologist Oncology specialist and a Hematologist in Smithtown, New York. Dr. Maresca is rated as a Distinguished provider by MediFind in the treatment of Chronic Familial Neutropenia. His top areas of expertise are Severe Congenital Neutropenia, Pulmonary Embolism, Chronic Familial Neutropenia, Bone Marrow Aspiration, and Endoscopy.

Distinguished in Chronic Familial Neutropenia
Dr. Ramamohana Kancherla
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Familial Neutropenia
Dr. Ramamohana Kancherla
Hematology Oncology | Hematology | Oncology

North Shore Hematology Oncology Associates PC

365 E Main St, 
Patchogue, NY 
 (11.3 miles away)
631-751-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ramamohana Kancherla is a Hematologist Oncology specialist and a Hematologist in Patchogue, New York. Dr. Kancherla is rated as a Distinguished provider by MediFind in the treatment of Chronic Familial Neutropenia. His top areas of expertise are Severe Congenital Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, Pulmonary Embolism, and Gastrostomy.

Distinguished in Chronic Familial Neutropenia
Dr. Doron Weiner
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Familial Neutropenia
Dr. Doron Weiner
Hematology Oncology | Hematology | Oncology

Mount Sinai School Of Medicine

1 Healthy Way, Mount Sinai Marathon Medic, 
Oceanside, NY 
 (32.2 miles away)
877-768-8462
Languages Spoken:
English
See accepted insurances

Doron Weiner is a Hematologist Oncology specialist and a Hematologist in Oceanside, New York. Dr. Weiner is rated as a Distinguished provider by MediFind in the treatment of Chronic Familial Neutropenia. His top areas of expertise are Essential Thrombocythemia, Thrombocytopenia, Febrile Neutropenia, and Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baer's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile